Therapeutic Strategies against Ebola Virus Infection

Ching Hsuan Liu; Yee Tung Hu; Shu Hui Wong; Liang Tzung Lin

doi:10.3390/v14030579

Therapeutic Strategies against Ebola Virus Infection

Ching Hsuan Liu, Yee Tung Hu, Shu Hui Wong, Liang Tzung Lin

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

Abstract

Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.

Original language	English
Article number	579
Journal	Viruses
Volume	14
Issue number	3
DOIs	https://doi.org/10.3390/v14030579
Publication status	Published - Mar 1 2022

Keywords

Antiviral
Drug development
Ebola virus
Ebola virus disease
Therapeutic

ASJC Scopus subject areas

Infectious Diseases
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v14030579

Cite this

@article{da90a7e1018e4db7a68b4ed0178e5962,

title = "Therapeutic Strategies against Ebola Virus Infection",

abstract = "Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.",

keywords = "Antiviral, Drug development, Ebola virus, Ebola virus disease, Therapeutic",

author = "Liu, {Ching Hsuan} and Hu, {Yee Tung} and Wong, {Shu Hui} and Lin, {Liang Tzung}",

note = "Funding Information: Funding: L.-T.L. is supported by the Ministry of Science and Technology of Taiwan (MOST110-2320-B-038-041-MY3). Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

day = "1",

doi = "10.3390/v14030579",

language = "English",

volume = "14",

journal = "Viruses",

issn = "1999-4915",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "3",

}

TY - JOUR

T1 - Therapeutic Strategies against Ebola Virus Infection

AU - Liu, Ching Hsuan

AU - Hu, Yee Tung

AU - Wong, Shu Hui

AU - Lin, Liang Tzung

N1 - Funding Information: Funding: L.-T.L. is supported by the Ministry of Science and Technology of Taiwan (MOST110-2320-B-038-041-MY3). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.

AB - Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vaccination programs. This review aims to highlight potential EBOV therapeutics and their target(s) of inhibition, serving as a summary of the literature to inform readers of the novel candidates available in the continued search for EBOV antivirals.

KW - Antiviral

KW - Drug development

KW - Ebola virus

KW - Ebola virus disease

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85126981281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126981281&partnerID=8YFLogxK

U2 - 10.3390/v14030579

DO - 10.3390/v14030579

M3 - Review article

C2 - 35336986

AN - SCOPUS:85126981281

SN - 1999-4915

VL - 14

JO - Viruses

JF - Viruses

IS - 3

M1 - 579

ER -

Therapeutic Strategies against Ebola Virus Infection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this